Fervo Energy gained 28% in a single session on September 1, recovering to $19.75 — yet it remains 12% below its one-month ago level, and a September 21 earnings date now looms over a stock that has punished buyers on each of its last two prints.
The ownership picture is the most underreported angle here. Three 13G filings landed in mid-August, all first-time disclosures. Devon Energy holds 12.5% of shares outstanding, Dipender Saluja (a venture backer) holds 11.9%, and DCVC's Zachary Bogue holds 6.3%. Together those three positions account for roughly 30% of the company. None carry activist intent — all are passive 13G filers — but the concentration is striking for a newly public geothermal developer. As with all 13D/G disclosures, these are as-last-reported around the 5% threshold; any holder dropping below that level may not file again. Devon's stake is particularly notable: a major oil and gas producer holding more than 12% of an enhanced geothermal company is a strategic signal, not a portfolio trade.
Short positioning neither explains Tuesday's move nor complicates the recovery story. Roughly 12.1 million shares are estimated short — a figure that has climbed about 19% over the past month even as the stock fell, suggesting bears were pressing into the post-earnings weakness. With borrow availability running at 191% — meaning nearly twice as many shares are available to lend as are currently borrowed — there is no squeeze mechanism at work here. Borrowing costs have eased to just over 1%, down from a brief spike toward 1.7% in late August. The ORTEX short score sits at 55.6, roughly in the middle of its recent range after peaking near 59 on August 24. None of this points to a technically driven bounce; the move came from somewhere else.
Options traders have shifted notably more bullish since the post-earnings lows. The put/call ratio is 0.49, essentially in line with its 20-day average of 0.50 and well below the 0.70 reading that marked the 52-week high. A month ago, before the August 12 results, the PCR sat in the low 0.20s — extremely call-heavy. After the print, it jumped to the high 0.50s as buyers hedged. The drift back toward the mean suggests the initial defensive response has passed, but there is no strong directional signal either way heading into the September 21 date.
The analyst picture remains constructive on direction but has repriced sharply on magnitude. After the August 12 results — which knocked the stock 16% on the day and 26% over the following five sessions — Baird cut its target from $50 to $35 while holding Outperform. In July, both Jefferies and BofA upgraded to Buy while simultaneously trimming targets to $34 and $36 respectively. The mean consensus target is approximately $43, which is still more than 100% above the current price. That gap is either an opportunity or a signal that the Street has not yet fully reset after a quarter that clearly surprised to the downside; the September 21 print will do more to resolve that question than anything else in the near term.
The pattern on earnings reactions is worth keeping in view: the two most recent prints produced a one-day move of -16% and -6% respectively, with five-day follow-through of -26% and -9%. Tuesday's 28% single-day rally — arriving outside of an earnings window — raises the stakes for what happens if the next number disappoints again.
See the live data behind this article on ORTEX.
Open FRVO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
